Hemphill, C. Scott; Sampat, Bhaven N. - In: Journal of Health Economics 31 (2012) 2, pp. 327-339
Observers worry that generic patent challenges are on the rise and reduce the effective market life of drugs. A related concern is that challenges disproportionately target high-sales drugs, reducing market life for these “blockbusters.”